Alterations of intestinal lipoprotein metabolism in diabetes mellitus and metabolic syndrome

Atherosclerosis Supplements

Volumn 17, Issue , 2015, Pages 12-16

  Arca, Marcello ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Cholesterol metabolism; Diabetes mellitus; Intestine; Metabolic syndrome; Postprandial lipemia

Indexed keywords

CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN;

ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL METABOLISM; DIABETES MELLITUS; HUMAN; HYPERLIPIDEMIA; INSULIN RESISTANCE; INTESTINE ABSORPTION; LIPID BLOOD LEVEL; LIPID METABOLISM; LIPOGENESIS; LIPOPROTEIN METABOLISM; METABOLIC SYNDROME X; PRIORITY JOURNAL; ANIMAL; BLOOD; INTESTINE; METABOLISM; POSTPRANDIAL STATE; TIME;

ANIMALS; CHOLESTEROL; DIABETES MELLITUS; HUMANS; HYPERLIPIDEMIAS; INSULIN RESISTANCE; INTESTINES; LIPOPROTEINS; METABOLIC SYNDROME X; POSTPRANDIAL PERIOD; TIME FACTORS;

EID: 84925018646     PISSN: 15675688     EISSN: 18785050     Source Type: Journal    
DOI: 10.1016/S1567-5688(15)50004-4     Document Type: Article

References (16)

1. Adiels M., Boren J., Caslake M.J., Stewart P., Soro A., Westerbacka J., Wennberg B., Olofsson S.O., Packard C., Taskinen M.R. Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia. Arterioscler Thromb Vasc Biol 2005 Aug, 25(8):1697-1703.
2. Moschetta A. Nuclear receptors and cholesterol metabolism in the intestine. Atheroscler Suppl 2015, 16:9-11. (this issue).
3. Kesäniemi Y.A., Miettinen T.A. Cholesterol absorption efficiency regulates plasma cholesterol level in the Finnish population. Eur J Clin Invest 1987 Oct, 17(5):391-395.
4. Rivellese A.A., De Natale C., Di Marino L., Patti L., Iovine C., Coppola S., Del Prato S., Riccardi G., Annuzzi G. Exogenous and endogenous postprandial lipid abnormalities in type 2 diabetic patients with optimal blood glucose control and optimal fasting triglyceride levels. J Clin Endocrinol Metab 2004 May, 89(5):2153-2159.
5. Kolovou G.D., Anagnostopoulou K.K., Pavlidis A.N., Salpea K.D., Iraklianou S.A., Tsarpalis K., Damaskos D.S., Manolis A., Cokkinos D.V. Postprandial lipemia in men with metabolic syndrome, hypertensives and healthy subjects. Lipids Health Dis 2005 Sep 30, 4:21.
6. Tomkin G.H. Targets for intervention in dyslipidemia in diabetes. Diabetes Care 2008 Feb, 31(Suppl 2):S241-S248.
7. Duez H., Lamarche B., Uffelman K.D., Valero R., Cohn J.S., Lewis G.F. Hyperinsulinemia is associated with increased production rate of intestinal apolipoprotein B-48-containing lipoproteins in humans. Arterioscler Thromb Vasc Biol 2006 Jun, 26(6):1357-1363.
8. Federico L.M., Naples M., Taylor D., Adeli K. Intestinal insulin resistance and aberrant production of apolipoprotein B48 lipoproteins in an animal model of insulin resistance and metabolic dyslipidemia: evidence for activation of protein tyrosine phosphatase-1B, extracellular signal-related kinase, and sterol regulatory element-binding protein-1c in the fructose-fed hamster intestine. Diabetes 2006 May, 55(5):1316-1326.
9. Hivert M.F., Sullivan L.M., Fox C.S., Nathan D.M., D'Agostino R.B., Wilson P.W., Meigs J.B. Associations of adiponectin, resistin, and tumor necrosis factor-alpha with insulin resistance. J Clin Endocrinol Metab 2008 Aug, 93(8):3165-3172.
10. Costandi J., Melone M., Zhao A., Rashid S. Human resistin stimulates hepatic overproduction of atherogenic ApoB-containing lipoprotein particles by enhancing ApoB stability and impairing intracellular insulin signaling. Circ Res 2011 Mar 18, 108(6):727-742.
11. Lally S., Tan C.Y., Owens D., Tomkin G.H. Messenger RNA levels of genes involved in dysregulation of postprandial lipoproteins in type 2 diabetes: the role of Niemann-Pick C1-like 1, ATP-binding cassette, transporters G5 and G8, and of microsomal triglyceride transfer protein. Diabetologia 2006 May, 49(5):1008-1016.
12. Altmann S.W., Davis H.R., Zhu L.J., Yao X., Hoos L.M., Tetzloff G., Iyer S.P., Maguire M., Golovko A., Zeng M., Wang L., Murgolo N., Graziano M.P. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 2004 Feb 20, 303(5661):1201-1204.
13. Tremblay A.J., Lamarche B., Cohn J.S., Hogue J.C., Couture P. Effect of ezetimibe on the in vivo kinetics of apoB-48 and apoB-100 in men with primary hypercholesterolemia. Arterioscler Thromb Vasc Biol 2006 May, 26(5):1101-1106.
14. Bozzetto L., Annuzzi G., Corte G.D., Patti L., Cipriano P., Mangione A., Riccardi G., Rivellese A.A. Ezetimibe beneficially influences fasting and postprandial triglyceride-rich lipoproteins in type 2 diabetes. Atherosclerosis 2011 Jul, 217(1):142-148.
15. Imke C., Rodriguez B.L., Grove J.S., McNamara J.R., Waslien C., Katz A.R., Willcox B., Yano K., Curb J.D. Are remnant-like particles independent predictors of coronary heart disease incidence? The Honolulu Heart study. Arterioscler Thromb Vasc Biol 2005 Aug, 25(8):1718-1722.
16. Mangat R., Warnakula S., Borthwick F., Hassanali Z., Uwiera R.R., Russell J.C., Cheeseman C.I., Vine D.F., Proctor S.D. Arterial retention of remnant lipoproteins ex vivo is increased in insulin resistance because of increased arterial biglycan and production of cholesterol-rich atherogenic particles that can be improved by ezetimibe in the JCR:LA-cp rat. J Am Heart Assoc 2012 Oct, 1(5):e003434.